Evidence map›Paper›PMID 36622034›Full record

ArticleJournal of visualized experiments : JoVE2022

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids.

Samuel Flashner, Cecilia Martin, Norihiro Matsuura, Masataka Shimonosono, Yasuto Tomita, Masaki Morimoto, Ogoegbunam Okolo, Victoria X Yu, Anuraag S Parikh, Andres J P Klein-Szanto and 6 more

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Samuel Flashner *Herbert Irving Comprehensive Cancer Center, Columbia University.
Cecilia Martin *Herbert Irving Comprehensive Cancer Center, Columbia University; Organoid and Cell Culture Core, Columbia University Digestive and Liver Diseases Research Center, Columbia University.
Norihiro MatsuuraHerbert Irving Comprehensive Cancer Center, Columbia University.
Masataka ShimonosonoHerbert Irving Comprehensive Cancer Center, Columbia University.
Yasuto TomitaHerbert Irving Comprehensive Cancer Center, Columbia University.
Masaki MorimotoHerbert Irving Comprehensive Cancer Center, Columbia University.
Ogoegbunam OkoloHerbert Irving Comprehensive Cancer Center, Columbia University.
Victoria X YuHerbert Irving Comprehensive Cancer Center, Columbia University; Department of Otolaryngology, Head and Neck Surgery, Columbia University.
Anuraag S ParikhHerbert Irving Comprehensive Cancer Center, Columbia University; Department of Otolaryngology, Head and Neck Surgery, Columbia University.
Andres J P Klein-SzantoHistopathology Facility, Fox Chase Cancer Center.
Kelley YanHerbert Irving Comprehensive Cancer Center, Columbia University; Organoid and Cell Culture Core, Columbia University Digestive and Liver Diseases Research Center, Columbia University.
Joel T GabreHerbert Irving Comprehensive Cancer Center, Columbia University; Division of Digestive and Liver Diseases, Department of Medicine, Columbia University.
Chao LuHerbert Irving Comprehensive Cancer Center, Columbia University; Department of Genetics and Development, Columbia University.
Fatemeh Momen-HeraviHerbert Irving Comprehensive Cancer Center, Columbia University; Section of Oral, Diagnostic and Rehabilitation Sciences, College of Dental Medicine, Columbia University.
Anil K RustgiHerbert Irving Comprehensive Cancer Center, Columbia University; Division of Digestive and Liver Diseases, Department of Medicine, Columbia University.
Hiroshi NakagawaHerbert Irving Comprehensive Cancer Center, Columbia University; Organoid and Cell Culture Core, Columbia University Digestive and Liver Diseases Research Center, Columbia University; Division of Digestive and Liver Diseases, Department of Medicine, Columbia University; hn2360@cumc.columbia.edu.
Columbia University · USFox Chase Cancer Center · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Transformed Esophageal Epithelial Cells and the Tumor MicroenvironmentP01CA098101 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RUSTGI, ANIL K · 2003 to 2023
$31.7M
Institutional Career Development CoreKL2TR001874 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GENKINGER, JEANINE M., SHIMBO, DAICHI · 2016 to 2025
$13.6M
The Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2M
Autophagy and esophageal tissue remodeling in EoER01DK114436 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI NAKAGAWA, HIROSHI · 2017 to 2024
$3.1M
The Role of the Microbiome and Notch Signaling in Esophageal AdenocarcinomaR01CA255298 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABRAMS, JULIAN · 2021 to 2025
$3.1M
Aldh2 and mitochondrial homeostasis in esophageal pathobiologyR01AA026297 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI Hiroshi Nakagawa · 2018 to 2026
$2.9M
Molecular basis for aberrant de novo DNA methylation in cancerR01CA266978 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Karim Jean Armache, Chao Lu · 2022 to 2026
$2.6M
Directing Cell Fate Along the Intestinal Enteroendocrine LineageDP2DK128801 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YAN, KELLEY · 2020 to 2020
$2.4M
Intestinal Stem Cell Function During Aging and Tumor InitiationR01AG067014 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YAN, KELLEY · 2020 to 2024
$2.3M
Cell Fate Regulation in Esophageal Progenitor CellsR01DK132251 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LU, CHAO, QUE, JIANWEN · 2022 to 2025
$2.3M
NCATS NIH HHS KL2 TR001874NCATS NIH HHS UL1 TR001873NCI NIH HHS L30 CA264714NCI NIH HHS P01 CA098101NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA255298NCI NIH HHS R01 CA266978NIAAA NIH HHS R01 AA026297NIA NIH HHS R01 AG067014NIDCR NIH HHS L30 DE029070NIDCR NIH HHS R01 DE031873NIDCR NIH HHS R21 DE031112NIDDK NIH HHS DP2 DK128801NIDDK NIH HHS L30 DK126621NIDDK NIH HHS P30 DK132710NIDDK NIH HHS R01 DK114436NIDDK NIH HHS R01 DK132251
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) is prevalent worldwide, accounting for 90% of all esophageal cancer cases each year, and is the deadliest of all human squamous cell carcinomas. Despite recent progress in defining the molecular changes accompanying ESCC initiation and development, patient prognosis remains poor. The functional annotation of these molecular changes is the necessary next step and requires models that both capture the molecular features of ESCC and can be readily and inexpensively manipulated for functional annotation. Mice treated with the tobacco smoke mimetic 4-nitroquinoline 1-oxide (4NQO) predictably form ESCC and esophageal preneoplasia. Of note, 4NQO lesions also arise in the oral cavity, most commonly in the tongue, as well as the forestomach, which all share the stratified squamous epithelium. However, these mice cannot be simply manipulated for functional hypothesis testing, as generating isogenic mouse models is time- and resource-intensive. Herein, we overcome this limitation by generating single cell-derived three-dimensional (3D) organoids from mice treated with 4NQO to characterize murine ESCC or preneoplastic cells ex vivo. These organoids capture the salient features of ESCC and esophageal preneoplasia, can be cheaply and quickly leveraged to form isogenic models, and can be utilized for syngeneic transplantation experiments. We demonstrate how to generate 3D organoids from normal, preneoplastic, and SCC murine esophageal tissue and maintain and cryopreserve these organoids. The applications of these versatile organoids are broad and include the utilization of genetically engineered mice and further characterization by flow cytometry or immunohistochemistry, the generation of isogeneic organoid lines using CRISPR technologies, and drug screening or syngeneic transplantation. We believe that the widespread adoption of the techniques demonstrated in this protocol will accelerate progress in this field to combat the severe burden of ESCC.

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHead and Neck NeoplasmsMouth NeoplasmsAnimalsCell Line, TumorCell ProliferationHumansMiceOrganoidsSquamous Cell Carcinoma of Head and Neck

Identifiers

PMID36622034
PMCPMC10037110
OpenAlexW4312116122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.